Long-term outcomes of Penile Squamous Cell Carcinoma (SCC) patients with Sarcomatoid variant compared to non-sarcomatoid group- An eUROGEN study
BAUS ePoster online library. Alnajjar H. 06/21/21; 319086; p4-8
Disclosure(s): N/A
Mr. Hussain Alnajjar
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
Sarcomatoid penile SCC has an aggressive behaviour with poor prognosis, and often associated with early haematogenous spread. Reports in the literature focusing on outcomes of this group of patients is sparse. The aim of this study was to review the management and outcomes of sarcomatoid SCC patients in a specialist centre.
Materials and Methods
A retrospective study using an institutional database consisting of patients treated for sarcomatoid penile SCC over a 10-year period. Patient demographics, recurrence rates, TNM staging, adjuvant treatments, type of primary surgery were recorded. CS survival was compared to non-sarcomatoid group. 5- year CS survival rates were calculated using KM curves (p <0.05 statistically significant).
Results
27 patients with sarcomatoid SCC were identified. Mean age was 69 years [range 43-96].
A total of 12 recurrences (3 localised and 9 nodal or distant metastases) with a mean time to recurrence of 12 months [1-60 months]. 11 (41%) patients underwent adjuvant chemoradiotherapy. 18/27 patients died (70%) with an average of 18 months from diagnosis [2 – 96 months].
244 non-sarcomatoid penile cancer were treated in the same time period. 5-year CSS was 32% vs. 76% for the sarcomatoid and the non-sarcomatoid groups respectively (p<0.0001).
Conclusions
This group of patients should be treated aggressively at an early stage in their diagnosis by a combination of surgical and adjuvant chemoradiotherapy. Patients presenting with advanced disease are more likely to benefit from neoadjuvant chemoradiation followed by surgery. Despite multidisciplinary efforts, survival and prognosis remain very poor.
Sarcomatoid penile SCC has an aggressive behaviour with poor prognosis, and often associated with early haematogenous spread. Reports in the literature focusing on outcomes of this group of patients is sparse. The aim of this study was to review the management and outcomes of sarcomatoid SCC patients in a specialist centre.
Materials and Methods
A retrospective study using an institutional database consisting of patients treated for sarcomatoid penile SCC over a 10-year period. Patient demographics, recurrence rates, TNM staging, adjuvant treatments, type of primary surgery were recorded. CS survival was compared to non-sarcomatoid group. 5- year CS survival rates were calculated using KM curves (p <0.05 statistically significant).
Results
27 patients with sarcomatoid SCC were identified. Mean age was 69 years [range 43-96].
A total of 12 recurrences (3 localised and 9 nodal or distant metastases) with a mean time to recurrence of 12 months [1-60 months]. 11 (41%) patients underwent adjuvant chemoradiotherapy. 18/27 patients died (70%) with an average of 18 months from diagnosis [2 – 96 months].
244 non-sarcomatoid penile cancer were treated in the same time period. 5-year CSS was 32% vs. 76% for the sarcomatoid and the non-sarcomatoid groups respectively (p<0.0001).
Conclusions
This group of patients should be treated aggressively at an early stage in their diagnosis by a combination of surgical and adjuvant chemoradiotherapy. Patients presenting with advanced disease are more likely to benefit from neoadjuvant chemoradiation followed by surgery. Despite multidisciplinary efforts, survival and prognosis remain very poor.
Introduction
Sarcomatoid penile SCC has an aggressive behaviour with poor prognosis, and often associated with early haematogenous spread. Reports in the literature focusing on outcomes of this group of patients is sparse. The aim of this study was to review the management and outcomes of sarcomatoid SCC patients in a specialist centre.
Materials and Methods
A retrospective study using an institutional database consisting of patients treated for sarcomatoid penile SCC over a 10-year period. Patient demographics, recurrence rates, TNM staging, adjuvant treatments, type of primary surgery were recorded. CS survival was compared to non-sarcomatoid group. 5- year CS survival rates were calculated using KM curves (p <0.05 statistically significant).
Results
27 patients with sarcomatoid SCC were identified. Mean age was 69 years [range 43-96].
A total of 12 recurrences (3 localised and 9 nodal or distant metastases) with a mean time to recurrence of 12 months [1-60 months]. 11 (41%) patients underwent adjuvant chemoradiotherapy. 18/27 patients died (70%) with an average of 18 months from diagnosis [2 – 96 months].
244 non-sarcomatoid penile cancer were treated in the same time period. 5-year CSS was 32% vs. 76% for the sarcomatoid and the non-sarcomatoid groups respectively (p<0.0001).
Conclusions
This group of patients should be treated aggressively at an early stage in their diagnosis by a combination of surgical and adjuvant chemoradiotherapy. Patients presenting with advanced disease are more likely to benefit from neoadjuvant chemoradiation followed by surgery. Despite multidisciplinary efforts, survival and prognosis remain very poor.
Sarcomatoid penile SCC has an aggressive behaviour with poor prognosis, and often associated with early haematogenous spread. Reports in the literature focusing on outcomes of this group of patients is sparse. The aim of this study was to review the management and outcomes of sarcomatoid SCC patients in a specialist centre.
Materials and Methods
A retrospective study using an institutional database consisting of patients treated for sarcomatoid penile SCC over a 10-year period. Patient demographics, recurrence rates, TNM staging, adjuvant treatments, type of primary surgery were recorded. CS survival was compared to non-sarcomatoid group. 5- year CS survival rates were calculated using KM curves (p <0.05 statistically significant).
Results
27 patients with sarcomatoid SCC were identified. Mean age was 69 years [range 43-96].
A total of 12 recurrences (3 localised and 9 nodal or distant metastases) with a mean time to recurrence of 12 months [1-60 months]. 11 (41%) patients underwent adjuvant chemoradiotherapy. 18/27 patients died (70%) with an average of 18 months from diagnosis [2 – 96 months].
244 non-sarcomatoid penile cancer were treated in the same time period. 5-year CSS was 32% vs. 76% for the sarcomatoid and the non-sarcomatoid groups respectively (p<0.0001).
Conclusions
This group of patients should be treated aggressively at an early stage in their diagnosis by a combination of surgical and adjuvant chemoradiotherapy. Patients presenting with advanced disease are more likely to benefit from neoadjuvant chemoradiation followed by surgery. Despite multidisciplinary efforts, survival and prognosis remain very poor.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}